Several PDE4-selective inhibitors have successfully reached the market, targeting diseases such as psoriasis, atopic dermatitis, chronic obstructive pulmonary disease (COPD), asthma and alleviating pain caused by smooth muscle spasm (Table 1). The gene discussed is PDE4A; the disease is asthma.